Literature DB >> 21053359

PRL-3 phosphatase and cancer metastasis.

Abdul Qader O Al-Aidaroos1, Qi Zeng.   

Abstract

The deregulated expression of members of the phosphatase of regenerating liver (PRL) family has been implicated in the metastatic progression of multiple human cancers. Importantly, PRL-1 and PRL-3 both possess the capacity to drive key steps in metastatic progression. Yet, little is known about the regulation and oncogenic mechanisms of this emerging class of dual-specificity phosphatases. This prospect article details the involvement of PRLs in the metastatic cascade, the regulatory mechanisms controlling PRL expression, and recent efforts in the characterization of PRL-modulated pathways and substrates using biochemical and high-throughput approaches. Current advances and future prospects in anti-cancer therapy targeting this family are also discussed.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21053359     DOI: 10.1002/jcb.22913

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  58 in total

1.  Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression.

Authors:  Yosuke Funato; Daisuke Yamazaki; Shin Mizukami; Lisa Du; Kazuya Kikuchi; Hiroaki Miki
Journal:  J Clin Invest       Date:  2014-10-27       Impact factor: 14.808

2.  PRL-3 mediates the protein maturation of ULBP2 by regulating the tyrosine phosphorylation of HSP60.

Authors:  Wai-Hang Leung; Queenie P Vong; Wenwei Lin; David Bouck; Susanne Wendt; Erin Sullivan; Ying Li; Rafijul Bari; Taosheng Chen; Wing Leung
Journal:  J Immunol       Date:  2015-02-16       Impact factor: 5.422

3.  Mechanism of thienopyridone and iminothienopyridinedione inhibition of protein phosphatases.

Authors:  Zhidian Zhang; Guennadi Kozlov; Yu Seby Chen; Kalle Gehring
Journal:  Medchemcomm       Date:  2019-04-05       Impact factor: 3.597

4.  PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.

Authors:  Xian-Ying Fang; Ran Song; Wei Chen; Yuan-Yuan Yang; Yan-Hong Gu; Yong-Qian Shu; Xu-Dong Wu; Xue-Feng Wu; Yang Sun; Yan Shen; Qiang Xu
Journal:  J Invest Dermatol       Date:  2015-04-10       Impact factor: 8.551

Review 5.  Molecular targets and pathways involved in liver metastasis of colorectal cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2015-06-24       Impact factor: 5.150

6.  Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.

Authors:  Zhen-Hua Sun; Ping Bu
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

Review 7.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

8.  PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Authors:  Min Thura; Abdul Qader Omer Al-Aidaroos; Wei Peng Yong; Koji Kono; Abhishek Gupta; You Bin Lin; Kousaku Mimura; Jean Paul Thiery; Boon Cher Goh; Patrick Tan; Ross Soo; Cheng William Hong; Lingzhi Wang; Suling Joyce Lin; Elya Chen; Sun Young Rha; Hyun Cheol Chung; Jie Li; Sayantani Nandi; Hiu Fung Yuen; Shu-Dong Zhang; Yeoh Khay Guan; Jimmy So; Qi Zeng
Journal:  JCI Insight       Date:  2016-06-16

Review 9.  Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.

Authors:  Yangyang Wang; Xinhui Wang; Cristina R Ferrone; Joseph H Schwab; Soldano Ferrone
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

10.  Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.

Authors:  Abdul Qader Omer Al-Aidaroos; Hiu Fung Yuen; Ke Guo; Shu Dong Zhang; Tae-Hoon Chung; Wee Joo Chng; Qi Zeng
Journal:  J Clin Invest       Date:  2013-07-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.